XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended 12 Months Ended 35 Months Ended 45 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2019
Dec. 31, 2018
Feb. 28, 2009
Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Unbilled contract asset     $ 180,000 $ 0    
Europe [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Unbilled contract asset     130,000      
Astellas Agreement [Member] | Japan [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent and time-based payments received           $ 40,100
Potential milestone payments   $ 132,500        
Commercial sales milestone   15,000        
Aggregate consideration received     77,600      
Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential milestone payments   22,500        
Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential milestone payments   $ 95,000        
Astellas Agreement [Member] | Europe [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent and time-based payments received         $ 320,000  
Potential milestone payments $ 425,000          
Aggregate consideration received     $ 410,000      
Percentage of joint development costs committed to fund 50.00%          
Additional consideration based on net sales description     low 20% range      
Estimated joint development extended service period       2023    
Transaction price and allocated to performance obligations     $ 130,000      
Revenue during period from performance obligations     129,500      
Unbilled contract asset     $ 130,000      
Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential milestone payments $ 90,000          
Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential milestone payments $ 335,000